On the occasion of the 37th World AIDS Day, the Chinese Association of STD and AIDS Prevention and Control and China Youth ...

Venture capital group Abingworth is reportedly trying to raise up to $1.5 billion in investment funding to support biopharma ...

Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics ...

The twice-yearly shot was 100% effective in preventing HIV infections in a study of women, and recently results published show it worked nearly as well in men.

The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...

I'm sometimes asked how I started in AIDS organizing. Although it’s hard to pin when it happened, I will always remember ...

Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...

The twice-yearly HIV prevention shot from Gilead Sciences has proven 100% effective in women and nearly as effective in men, ...

South Africa is a good example of a country that would benefit from the discovery of a cure. South Africa’s been providing ...

Biotech giant Gilead Sciences, Inc.’s GILD shares have risen 44.2% in the past six months compared with the industry’s growth of 1.1%. The stock has also outperformed the sector and the S&P 500. It ...

According to a study published in the New England Journal of Medicine, twice-yearly injection of Lenacapavir offers a 96 percent ...

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...